Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?

× No keyword cloud information.

13 in total

Review 1. Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.

Authors: Xiongwen Yang; Xiong Pan; Xiaoshu Cheng; Yingzhang Cheng; Yukang Kuang
Journal: Int J Clin Pharm Date: 2015-07-15

Review 2. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.

Authors: Rebecca L Stone; Anil K Sood; Robert L Coleman
Journal: Lancet Oncol Date: 2010-03-10 Impact factor: 41.316

Review 3. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?

Authors: Christos Vaklavas; Daniel Lenihan; Razelle Kurzrock; Apostolia Maria Tsimberidou
Journal: Oncologist Date: 2010-02-05

4. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.

Authors: Shuiying Hu; Zhaoyuan Chen; Ryan Franke; Shelley Orwick; Ming Zhao; Michelle A Rudek; Alex Sparreboom; Sharyn D Baker
Journal: Clin Cancer Res Date: 2009-09-22 Impact factor: 12.531

5. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Authors: Michael L Maitland; George L Bakris; Henry R Black; Helen X Chen; Jean-Bernard Durand; William J Elliott; S Percy Ivy; Carl V Leier; Joann Lindenfeld; Glenn Liu; Scot C Remick; Richard Steingart; W H Wilson Tang
Journal: J Natl Cancer Inst Date: 2010-03-29 Impact factor: 13.506

Review 6. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.

Authors: Kelly L Snider; Michael L Maitland
Journal: Target Oncol Date: 2009-04-17 Impact factor: 4.493

Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?

Review 1. Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.

Review 2. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.

Review 3. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?

4. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.

5. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Review 6. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.

Review 7. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.

Review 8. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.

9. The bevacizumab experience in advanced renal cell carcinoma.

Review 10. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.